Topics:
Breast Cancer • Radiation Oncology
In women with locally advanced HER2+ breast cancer who have had a complete response to neoadjuvant chemotherapy, what factors impact your decision to offer PMRT?
Does your recommendation change for women with HER2- disease?
Answer from: Radiation Oncologist at Community Practice
Currently, the use of PMRT should be based on pre treatment staging. If pretreatment staging is stage III, I would recommend RT. If pretreatment nodal staging is IIB would favor observation but would also consider for B51 study randomizing between RT vs observation.
Sign in or Register to read more
Answer from: Radiation Oncologist at Academic Institution
For my practice, any node positive patients (even T2N1) eligible for B51 would be offered enrollment. Off-protocol I would treat.
Any patient with up-front cT4 or cN2+ disease (not eligible for B51) gets PMRT.
cT3N0 prior to chemotherapy would be an individualized discussion with the patient but w...